Physician profile
John A Sturges
NPI 1164507166
$8,938.40
in general payments reported to CMS, 2019-2025
37 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 93% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $637 · 2021: $775 · 2022: $791 · 2023: $1,691 · 2024: $2,289 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,980.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,529.91 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $928.82 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $712.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $625.11 | 2020-2025 | Evenity, Prolia, Krystexxa |
| Janssen Pharmaceuticals, INC | $580.26 | 2023-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $531.66 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $520.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $508.87 | 2019-2025 | |
| Exact Sciences Corporation | $426.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $391.69 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $265.01 | 2019-2025 | |
| Abbott Laboratories | $240.01 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $180.58 | 2019-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $143.70 | 2019-2022 | |
| Zimvie INC. | $134.25 | 2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.61 | 2019-2025 | Jardiance |
| Eisai INC. | $108.53 | 2020-2025 | |
| Axsome Therapeutics, INC. | $99.19 | 2025 | Auvelity, Symbravo |
| Corcept Therapeutics | $95.71 | 2025 | Korlym |
| Radius Health, INC. | $90.50 | 2019-2022 | |
| Amarin Pharma, INC. | $90.22 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $68.49 | 2021 | |
| Fidia Pharma USA INC. | $52.59 | 2024-2025 | Hymhyn, Hym/Hyn |
| Teva Pharmaceuticals USA, INC. | $50.18 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $49.46 | 2022 | |
| Vanda Pharmaceuticals INC. | $46.94 | 2025 | Fanapt |
| Grifols USA, LLC | $43.04 | 2024-2025 | Prolastin-C Liquid |
| Biomerieux INC | $43.00 | 2025 | Biofire Spotfire Control Station |
| Glaxosmithkline, LLC. | $40.40 | 2023 | Shingrix, Arexvy |
| Allergan, INC. | $35.19 | 2019-2020 | |
| Horizon Therapeutics Plc | $32.46 | 2021 | |
| Therapeuticsmd, INC. | $30.13 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $28.09 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $26.77 | 2025 | Eliquis |
| Ani Pharmaceuticals, INC. | $25.13 | 2025 | Purified Cortrophin Gel |
| Dexcom, INC. | $23.99 | 2025 | Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $21.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sturges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.